Summit, Akeso’s China approval celebration cut short as survival benefit degrades
Ivonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines over time.
Summit, Akeso’s China approval celebration cut short as survival benefit degrades Read More »
